memantine has been researched along with Disease Exacerbation in 76 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD." | 9.19 | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. ( Arroyo, LM; Asthana, S; Bakshi, RS; Chen, P; Chopra, MP; Craft, S; Cruz, AR; Dysken, MW; Gordon, K; Guarino, PD; Heidebrink, JL; Kowall, NW; Llorente, M; Loreck, DJ; Love, S; Malphurs, J; McCarten, JR; Mintzer, JE; Monnell, KA; Pallaki, M; Peduzzi, PN; Prieto, S; Sano, M; Schellenberg, GD; Segal, Y; Thielke, S; Tomaska, J; Trapp, G; Turvey, CL; Vertrees, JE; Vidal-Cardona, A; Woodman, C; Zachariah, S, 2014) |
| "To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression." | 9.13 | Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. ( Berghold, A; Enzinger, C; Fazekas, F; Kolassa, H; Ofner, P; Pendl, B; Ropele, S; Schmidt, H; Schmidt, R; Windisch, M, 2008) |
| "These results extend previous findings that demonstrated the efficacy and safety of memantine in the treatment of patients with moderate to severe Alzheimer disease." | 9.12 | A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2006) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 7.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| "Memantine was administered orally either semiprophylactically, from day 7 postinoculation (PI), or therapeutically, 10 to 11 days PI." | 5.31 | Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. ( Bolton, C; Paul, C, 2002) |
| "Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD." | 5.19 | Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. ( Arroyo, LM; Asthana, S; Bakshi, RS; Chen, P; Chopra, MP; Craft, S; Cruz, AR; Dysken, MW; Gordon, K; Guarino, PD; Heidebrink, JL; Kowall, NW; Llorente, M; Loreck, DJ; Love, S; Malphurs, J; McCarten, JR; Mintzer, JE; Monnell, KA; Pallaki, M; Peduzzi, PN; Prieto, S; Sano, M; Schellenberg, GD; Segal, Y; Thielke, S; Tomaska, J; Trapp, G; Turvey, CL; Vertrees, JE; Vidal-Cardona, A; Woodman, C; Zachariah, S, 2014) |
| "We sought to determine whether the extended MAPT haplotype was associated with the worsening of delusions and hallucinations in a combined cohort of 95 patients who participated in 2 clinical trials of treatment with memantine." | 5.19 | Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. ( Ballard, C; Corbett, A; Creese, B; Fox, C; Jones, E, 2014) |
| "To study the feasibility of multimodal neuroimaging in mild to moderate Alzheimer disease (AD) and to estimate the size of possible treatment effects of memantine on potential functional, structural and metabolic biomarkers of disease progression." | 5.13 | Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. ( Berghold, A; Enzinger, C; Fazekas, F; Kolassa, H; Ofner, P; Pendl, B; Ropele, S; Schmidt, H; Schmidt, R; Windisch, M, 2008) |
| "These results extend previous findings that demonstrated the efficacy and safety of memantine in the treatment of patients with moderate to severe Alzheimer disease." | 5.12 | A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2006) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 3.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| "Early AD (eAD) includes mild cognitive impairment (MCI) due to AD and mild AD dementia." | 3.01 | Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease. ( Ballard, C; Garcia, MJ; Gsteiger, S; Lang, S; Leadley, R; Ross, J; Vinand, E, 2023) |
| "Memantine was not associated with a significant frequency of adverse events." | 2.71 | Memantine in moderate-to-severe Alzheimer's disease. ( Doody, R; Ferris, S; Möbius, HJ; Reisberg, B; Schmitt, F; Stöffler, A, 2003) |
| "In patients with mild to moderate vascular dementia, memantine 20 mg/d improved cognition consistently across different cognitive scales, with at least no deterioration in global functioning and behavior." | 2.70 | Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). ( Forette, F; Möbius, HJ; Orgogozo, JM; Rigaud, AS; Stöffler, A, 2002) |
| "The behavioral variant of frontotemporal dementia (bvFTD), characterized by early behavioral disorders, is a rare disease (about 5." | 2.50 | [Frontal variant of frontotemporal dementia]. ( Boutoleau-Bretonniere, C; Lebouvier, T; Vercelletto, M, 2014) |
| "Memantine now has a considerable database of published studies and is associated with benefits in aspects of behaviour, cognition and communication, and on clinical progression." | 2.48 | A review of the effects of memantine on clinical progression in Alzheimer's disease. ( Wilkinson, D, 2012) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | 2.48 | Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. ( Baskys, A; Cheng, JX, 2012) |
| "Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder." | 2.44 | Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008) |
| "Glaucoma is a neurodegenerative disease for which the neuropathic pathology has been studied since 1972." | 2.44 | History of neuroprotection and rationale as a therapy for glaucoma. ( Levin, LA; Peeples, P, 2008) |
| "It is essential to recognize and treat psychosis in Parkinson's disease for several reasons." | 2.44 | Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective? ( Fernandez, HH; Zahodne, LB, 2008) |
| "Alzheimer's disease is a chronic, progressive illness that requires long-term management." | 2.43 | Alzheimer's disease care management plan: maximizing patient care. ( Treinkman, A, 2005) |
| "Research into Alzheimer's disease (AD) pathology has identified several underlying disease processes that are potential targets for drug discovery and development." | 2.42 | NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. ( Farlow, MR, 2004) |
| "Potential predictors of disease progression, including age, gender, the type of ChEI, and Apolipoprotein E (APOE) genotype, were also analyzed." | 1.48 | Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication. ( Chou, PS; Lin, SH; Su, HC; Sung, PS; Wu, MN; Yang, YH, 2018) |
| "Overall, worsening and disease progression as measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) and Clinical Dementia Rating (CDR) did not correlate with the duration of AChE-I treatment." | 1.48 | Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial. ( Bauer, C; Frölich, L; Heuser, I; Joachim, LK; Kornhuber, J; Maier, W; Peters, O; Rüther, E; Wiltfang, J, 2018) |
| "Memantine was the dominant strategy with cost savings of €3739 (30 041 NOK) per patient." | 1.38 | Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. ( Aarsland, D; Cochran, J; Grishchenko, M; Lamure, M; Rive, B; Toumi, M, 2012) |
| "Treatment with memantine delays clinical worsening in patients with moderate to severe AD when compared with placebo." | 1.38 | Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. ( Hartmann, S; Hellweg, R; Janetzky, W; Wirth, Y, 2012) |
| "Currently there is no treatment for juvenile Batten disease, a fatal childhood neurodegenerative disorder caused by mutations in the CLN3 gene." | 1.38 | Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. ( Cooper, JD; Kovács, AD; Pearce, DA; Ramji, S; Saje, A; Wong, A, 2012) |
| "Patients with Alzheimer's disease (AD) who deteriorate rapidly are likely to have a poorer prognosis." | 1.37 | Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire. ( Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F, 2011) |
| "Hyperammonemia is a main contributor to brain herniation and mortality in acute liver failure (ALF)." | 1.35 | Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain. ( Agusti, A; Boix, J; Cauli, O; Felipo, V; Piedrafita, B; Rodrigo, R, 2008) |
| "Many patients with early symptoms of Alzheimer's disease (AD) first seek help from their primary care providers (PCPs)." | 1.35 | Alzheimer's disease: Seeing the signs early. ( Leifer, BP, 2009) |
| "Memantine was administered orally either semiprophylactically, from day 7 postinoculation (PI), or therapeutically, 10 to 11 days PI." | 1.31 | Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. ( Bolton, C; Paul, C, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (42.11) | 29.6817 |
| 2010's | 40 (52.63) | 24.3611 |
| 2020's | 4 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardi, G | 1 |
| Lombardi, N | 1 |
| Bettiol, A | 1 |
| Crescioli, G | 1 |
| Ferrari, C | 1 |
| Lucidi, G | 1 |
| Polito, C | 1 |
| Berti, V | 1 |
| Bessi, V | 1 |
| Bagnoli, S | 1 |
| Nacmias, B | 1 |
| Vannacci, A | 1 |
| Sorbi, S | 1 |
| Garcia, MJ | 3 |
| Leadley, R | 3 |
| Lang, S | 3 |
| Ross, J | 3 |
| Vinand, E | 3 |
| Ballard, C | 4 |
| Gsteiger, S | 3 |
| Anderson, A | 1 |
| Malone, M | 1 |
| Honjo, Y | 1 |
| Ide, K | 1 |
| Takechi, H | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 4 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 7 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 3 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 3 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Yang, YH | 1 |
| Wu, MN | 1 |
| Chou, PS | 1 |
| Su, HC | 1 |
| Lin, SH | 1 |
| Sung, PS | 1 |
| Joachim, LK | 1 |
| Frölich, L | 2 |
| Rüther, E | 2 |
| Wiltfang, J | 1 |
| Maier, W | 2 |
| Kornhuber, J | 2 |
| Bauer, C | 1 |
| Heuser, I | 3 |
| Peters, O | 2 |
| Weinreb, RN | 1 |
| Liebmann, JM | 1 |
| Cioffi, GA | 1 |
| Goldberg, I | 1 |
| Brandt, JD | 1 |
| Johnson, CA | 1 |
| Zangwill, LM | 1 |
| Schneider, S | 1 |
| Badger, H | 1 |
| Bejanian, M | 1 |
| Di Santo, SG | 1 |
| Prinelli, F | 1 |
| Adorni, F | 1 |
| Caltagirone, C | 1 |
| Musicco, M | 1 |
| Conde-Sala, JL | 1 |
| Garre-Olmo, J | 1 |
| Vilalta-Franch, J | 1 |
| Llinàs-Reglà, J | 1 |
| Turró-Garriga, O | 1 |
| Lozano-Gallego, M | 1 |
| Hernández-Ferràndiz, M | 1 |
| Pericot-Nierga, I | 1 |
| López-Pousa, S | 1 |
| van de Glind, EM | 1 |
| van Enst, WA | 1 |
| van Munster, BC | 1 |
| Olde Rikkert, MG | 1 |
| Scheltens, P | 1 |
| Scholten, RJ | 1 |
| Hooft, L | 1 |
| Finn, R | 1 |
| Kovács, AD | 2 |
| Pearce, DA | 2 |
| Wilkinson, D | 3 |
| Wirth, Y | 2 |
| Goebel, C | 1 |
| Ghezzi, L | 1 |
| Scarpini, E | 1 |
| Galimberti, D | 1 |
| Dysken, MW | 1 |
| Sano, M | 1 |
| Asthana, S | 1 |
| Vertrees, JE | 1 |
| Pallaki, M | 1 |
| Llorente, M | 1 |
| Love, S | 1 |
| Schellenberg, GD | 1 |
| McCarten, JR | 1 |
| Malphurs, J | 1 |
| Prieto, S | 1 |
| Chen, P | 1 |
| Loreck, DJ | 1 |
| Trapp, G | 1 |
| Bakshi, RS | 1 |
| Mintzer, JE | 1 |
| Heidebrink, JL | 1 |
| Vidal-Cardona, A | 1 |
| Arroyo, LM | 1 |
| Cruz, AR | 1 |
| Zachariah, S | 1 |
| Kowall, NW | 1 |
| Chopra, MP | 1 |
| Craft, S | 1 |
| Thielke, S | 1 |
| Turvey, CL | 1 |
| Woodman, C | 1 |
| Monnell, KA | 1 |
| Gordon, K | 1 |
| Tomaska, J | 1 |
| Segal, Y | 1 |
| Peduzzi, PN | 1 |
| Guarino, PD | 1 |
| Wallesch, CW | 1 |
| Ritchie, CW | 1 |
| Bajwa, J | 1 |
| Coleman, G | 1 |
| Hope, K | 1 |
| Jones, RW | 1 |
| Lawton, M | 1 |
| Marven, M | 1 |
| Passmore, P | 1 |
| Boutoleau-Bretonniere, C | 1 |
| Lebouvier, T | 1 |
| Vercelletto, M | 1 |
| Zemek, F | 1 |
| Drtinova, L | 1 |
| Nepovimova, E | 1 |
| Sepsova, V | 1 |
| Korabecny, J | 1 |
| Klimes, J | 1 |
| Kuca, K | 1 |
| Hermann, DM | 1 |
| Creese, B | 1 |
| Corbett, A | 1 |
| Jones, E | 1 |
| Fox, C | 1 |
| Saint-Laurent Thibault, C | 1 |
| Özer Stillman, I | 1 |
| Getsios, D | 1 |
| Proskorovsky, I | 1 |
| Hernandez, L | 1 |
| Dixit, S | 1 |
| Hu, S | 1 |
| Clay, E | 1 |
| Toumi, M | 2 |
| Milea, D | 1 |
| Törmälehto, SM | 1 |
| Martikainen, JA | 1 |
| Väätäinen, ST | 1 |
| Hallikainen, IT | 1 |
| Hallikainen, M | 1 |
| Bell, JS | 1 |
| Koivisto, AM | 1 |
| Ruthirakuhan, M | 1 |
| Herrmann, N | 1 |
| Suridjan, I | 1 |
| Abraham, EH | 1 |
| Farber, I | 1 |
| Lanctôt, KL | 1 |
| Schmidt, R | 1 |
| Ropele, S | 1 |
| Pendl, B | 1 |
| Ofner, P | 1 |
| Enzinger, C | 1 |
| Schmidt, H | 1 |
| Berghold, A | 1 |
| Windisch, M | 1 |
| Kolassa, H | 1 |
| Fazekas, F | 1 |
| Cauli, O | 1 |
| Rodrigo, R | 1 |
| Boix, J | 1 |
| Piedrafita, B | 1 |
| Agusti, A | 1 |
| Felipo, V | 1 |
| Ruis, J | 1 |
| Merims, D | 1 |
| Freedman, M | 1 |
| Mecocci, P | 1 |
| Bladström, A | 1 |
| Stender, K | 1 |
| Kuprjanowicz, L | 1 |
| Karczewicz, D | 1 |
| Leifer, BP | 1 |
| Mayeux, R | 1 |
| Levine, TD | 1 |
| Bowser, R | 1 |
| Hank, N | 1 |
| Saperstein, D | 1 |
| Bloudek, LM | 1 |
| Spackman, DE | 1 |
| Veenstra, DL | 1 |
| Sullivan, SD | 1 |
| Riepe, MW | 1 |
| Janetzky, W | 2 |
| Lemming, OM | 1 |
| Carcaillon, L | 1 |
| Berrut, G | 1 |
| Sellal, F | 1 |
| Dartigues, JF | 1 |
| Gillette, S | 1 |
| Pere, JJ | 1 |
| Bourdeix, I | 1 |
| Hjermind, LE | 1 |
| Law, I | 1 |
| Jønch, A | 1 |
| Stokholm, J | 1 |
| Nielsen, JE | 1 |
| Bisaga, A | 1 |
| Sullivan, MA | 1 |
| Cheng, WY | 1 |
| Carpenter, KM | 1 |
| Mariani, JJ | 1 |
| Levin, FR | 1 |
| Raby, WN | 1 |
| Nunes, EV | 1 |
| Gravitz, L | 1 |
| Rive, B | 1 |
| Aarsland, D | 1 |
| Grishchenko, M | 1 |
| Cochran, J | 1 |
| Lamure, M | 1 |
| Massoud, F | 1 |
| Léger, GC | 1 |
| Atri, A | 1 |
| Stefanacci, RG | 1 |
| Mielke, MM | 1 |
| Leoutsakos, JM | 1 |
| Corcoran, CD | 1 |
| Green, RC | 1 |
| Norton, MC | 1 |
| Welsh-Bohmer, KA | 1 |
| Tschanz, JT | 1 |
| Lyketsos, CG | 1 |
| Aisen, PS | 1 |
| Cummings, J | 1 |
| Schneider, LS | 1 |
| Hellweg, R | 1 |
| Hartmann, S | 1 |
| Lorenz, D | 1 |
| Fesche, A | 1 |
| Schmidtke, K | 1 |
| Hüll, M | 1 |
| Perneczky, R | 1 |
| Möller, HJ | 1 |
| Jessen, F | 1 |
| Jahn, H | 1 |
| Luckhaus, C | 1 |
| Gertz, HJ | 1 |
| Schröder, J | 1 |
| Pantel, J | 1 |
| Teipel, S | 1 |
| Wellek, S | 1 |
| Saje, A | 1 |
| Wong, A | 1 |
| Ramji, S | 1 |
| Cooper, JD | 1 |
| Baskys, A | 1 |
| Cheng, JX | 1 |
| Reisberg, B | 2 |
| Doody, R | 2 |
| Stöffler, A | 3 |
| Schmitt, F | 2 |
| Ferris, S | 2 |
| Möbius, HJ | 3 |
| Winblad, B | 1 |
| Jelic, V | 1 |
| Grossberg, GT | 1 |
| Corey-Bloom, J | 1 |
| Small, GW | 1 |
| Tariot, PN | 1 |
| Farlow, MR | 1 |
| Beister, A | 1 |
| Kraus, P | 1 |
| Kuhn, W | 1 |
| Dose, M | 1 |
| Weindl, A | 1 |
| Gerlach, M | 1 |
| Greenfield, DS | 1 |
| Girkin, C | 1 |
| Kwon, YH | 1 |
| Small, SA | 1 |
| Treinkman, A | 1 |
| Ridha, BH | 1 |
| Josephs, KA | 1 |
| Rossor, MN | 1 |
| Jönsson, L | 1 |
| Johannsen, P | 1 |
| Rose, DZ | 1 |
| Cummings, JL | 1 |
| Andersen, HF | 1 |
| Green, C | 1 |
| Jakovljevic, M | 1 |
| Vuksan-Cusa, B | 1 |
| Topic, R | 1 |
| Levin, LA | 1 |
| Peeples, P | 1 |
| Zahodne, LB | 1 |
| Fernandez, HH | 1 |
| Morrison, LJ | 1 |
| Liao, S | 1 |
| Marx, J | 1 |
| Paul, C | 1 |
| Bolton, C | 1 |
| Orgogozo, JM | 1 |
| Rigaud, AS | 1 |
| Forette, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)[NCT00235716] | Phase 3 | 613 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence[NCT00476242] | Phase 2/Phase 3 | 82 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457] | Phase 3 | 60 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | ||
| A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00196703] | Phase 4 | 30 participants | Interventional | 2005-03-31 | Recruiting | ||
| A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00640198] | Phase 4 | 28 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Survival analysis of death from any cause. (NCT00235716)
Timeframe: up to 4 years
| Intervention | participants (Number) |
|---|---|
| Vitamin E | 26 |
| Memantine | 39 |
| Vitamin E + Memantine | 32 |
| Placebo | 31 |
The Dependence Scale assesses the level of assistance needed by patients with Alzheimer's disease for activities of daily living. The scale yields six levels of dependence: no assistance required (Level 0); requires occasional reminders (Level 1); requires frequent reminders and/or help with household chores (Level 2); needs daily supervision (Level 3); needs to be dressed, toileted or fed (Level 4); needs to be transferred, diapered or tube fed (Level 5). (NCT00235716)
Timeframe: Every 6 months to a maximum of 4 years
| Intervention | participants (Number) |
|---|---|
| Vitamin E | 80 |
| Memantine | 87 |
| Vitamin E + Memantine | 87 |
| Placebo | 79 |
The Alzheimer's Disease Assessment Scale (ADAS) is a 21-item scale designed to assess the severity of cognitive and non-cognitive behavioral impairments in patients with Alzheimer's disease. The cognitive portion of the scale (ADAS-cog) consists of 11 items to assess memory, language, and praxis functions. The ADAS-cog total score ranges from 0 (no errors) to 70 (severe cognitive impairment). Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | 1.11 | 3.32 | 5.69 | 6.73 | 7.64 | 8.31 | 8.24 | 11.74 | 6.38 |
| Placebo | 3.04 | 4.26 | 6.04 | 6.71 | 8.90 | 10.77 | 10.61 | 10.85 | 7.78 |
| Vitamin E | 1.38 | 2.40 | 4.34 | 4.32 | 7.87 | 9.00 | 10.35 | 10.73 | 5.97 |
| Vitamin E + Memantine | 1.53 | 2.48 | 3.46 | 5.76 | 5.85 | 8.26 | 7.97 | 9.70 | 6.13 |
The primary outcome of the study was the Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS/ADL) Inventory. The ADCS/ADL Inventory is designed to assess functional abilities to perform activities of daily living in Alzheimer patients with a broad range of dementia severity. The total score ranges from 0 to 78 with higher scores indicating greater abilities. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -2.40 | -6.99 | -9.32 | -14.06 | -18.30 | -18.78 | -23.48 | -24.60 | -14.98 |
| Placebo | -4.52 | -8.11 | -10.21 | -16.18 | -19.67 | -24.82 | -28.13 | -27.55 | -16.96 |
| Vitamin E | -1.72 | -4.29 | -8.01 | -11.88 | -15.84 | -19.71 | -25.30 | -26.55 | -13.81 |
| Vitamin E + Memantine | -2.78 | -6.60 | -7.98 | -12.82 | -15.66 | -18.89 | -23.44 | -29.25 | -15.20 |
The Caregiver Activity Survey (CAS) was developed to measure the time caregivers spend aiding Alzheimer patients with their day-to-day activities. The CAS consists of six items that ask for an estimate in hours and minutes of the time that the caregiver spent during the previous 24 hours performing these particular activities. The six CAS items are as follows: 1) communication with the person, 2) using transportation, 3) dressing, 4) eating, 5) looking after one's appearance, and 6) supervising the person. The more caregiving hours the worse the patient's functioning level. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | hours per day (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | 0.99 | 2.72 | 3.77 | 3.06 | 5.22 | 5.72 | 9.46 | 9.27 | 5.52 |
| Placebo | 1.20 | 1.89 | 3.16 | 3.45 | 4.36 | 10.68 | 10.62 | 12.17 | 5.14 |
| Vitamin E | -0.93 | -0.18 | 2.12 | 1.60 | 4.14 | 7.69 | 4.95 | 10.17 | 3.35 |
| Vitamin E + Memantine | 1.08 | 1.39 | 2.69 | 2.82 | 3.41 | 4.90 | 5.48 | 13.80 | 5.00 |
The Mini-Mental State Examination (MMSE) briefly and objectively assess cognitive status in psychiatric patients with cognitive impairment. The MMSE questions are grouped into seven categories, each representing a different cognitive domain. The MMSE yields a total score that ranges from 0 for a patient who gives no correct response to a score of 30 for a patient who makes no errors. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -0.24 | -1.09 | -2.62 | -3.44 | -3.79 | -4.26 | -4.59 | -5.98 | -3.05 |
| Placebo | -0.34 | -1.39 | -2.21 | -2.90 | -3.26 | -3.87 | -4.68 | -5.42 | -3.16 |
| Vitamin E | -0.35 | -0.95 | -2.00 | -2.62 | -3.67 | -4.97 | -4.84 | -5.26 | -2.97 |
| Vitamin E + Memantine | -0.20 | -0.65 | -1.22 | -2.29 | -3.16 | -3.69 | -3.80 | -5.70 | -2.80 |
The Neuropsychiatric Inventory (NPI) assesses psychological and behavioral problems in patients with dementia. For each of twelve domains, there are four scores: frequency, severity, total frequency x severity, and caregiver distress. The frequency x severity total scores from each domain are summed for an overall total score that ranges from 0 to 144. The total caregiver distress scores are also summed for an overall total caregiver distress score that ranges from 0 to 60. The secondary endpoint for the trial will be the overall frequency times severity total score. Outcome analysis is average least square means change from baseline. (NCT00235716)
Timeframe: 6, 12, 18, 24, 30, 36, 42 and 48 months minus baseline
| Intervention | units on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 6 months minus baseline | 12 months minus baseline | 18 months minus baseline | 24 months minus baseline | 30 months minus baseline | 36 months minus baseline | 42 months minus baseline | 48 months minus baseline | Average change from baseline | |
| Memantine | -0.20 | 0.31 | 1.18 | 4.29 | 2.62 | 3.24 | 3.63 | 2.79 | 1.87 |
| Placebo | 0.46 | 1.08 | 4.06 | 3.59 | 1.66 | 0.60 | 3.64 | 0.30 | 2.26 |
| Vitamin E | -1.24 | -1.04 | 0.93 | 2.16 | 3.21 | 2.15 | 0.81 | -0.60 | 0.79 |
| Vitamin E + Memantine | -0.47 | -0.17 | 0.41 | 1.98 | 2.16 | 2.79 | 1.85 | 5.14 | 1.79 |
Range 0- 100 ( 0= no craving; 100= very strong craving (NCT00476242)
Timeframe: Average of twice weekly assessments for 12 weeks of study or length of participation
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo and Vivitrol | 18.47 |
| Memantine and Vivitrol | 15.74 |
Opiate use was qualified by the number of opiate positive urine results. (NCT00476242)
Timeframe: 3x/week during 12 weeks of the trial or study participation
| Intervention | Percent of total urine samples (Median) |
|---|---|
| Memantine and Vivitrol | 9 |
| Placebo and Vivitrol | 10 |
(NCT00476242)
Timeframe: Week 12
| Intervention | participants (Number) |
|---|---|
| Memantine and Vivitrol | 12 |
| Placebo and Vivitrol | 19 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | -1.9 |
| Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | 4.4 |
| Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 1 |
| Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
| Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
| Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | number of items recalled (Mean) | |||
|---|---|---|---|---|
| Letter fluency | Category fluency | Digit symbol | Digits backwards | |
| Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
| Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
28 reviews available for memantine and Disease Exacerbation
| Article | Year |
|---|---|
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Disease Progression; Hu | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statis | 2013 |
Pharmacological treatment of dementia: a scoping review of systematic reviews.
Topics: Aged; Aged, 80 and over; Behavior; Cholinesterase Inhibitors; Cognition Disorders; Data Interpretati | 2013 |
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Diagnostic and Statistical Manual of Mental D | 2014 |
Disease-modifying drugs in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Disease Progression; D | 2013 |
[Pharmacological and non-pharmacological treatment of Alzheimer's dementia].
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Combined Modality Therapy; Disea | 2013 |
[Frontal variant of frontotemporal dementia].
Topics: Aged; Cholinesterase Inhibitors; Dementia; Disease Progression; France; Frontotemporal Dementia; Hum | 2014 |
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Progression | 2014 |
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Ac | 2016 |
Cognitive and behavioural impairment in Parkinson's disease.
Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo | 2008 |
[Neuroprotection in glaucoma].
Topics: Betaxolol; Brimonidine Tartrate; Disease Progression; Glaucoma; Guanidines; Humans; Memantine; Neuro | 2007 |
Clinical practice. Early Alzheimer's disease.
Topics: Age of Onset; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Diagnosis, Differential; Disease P | 2010 |
A review of the effects of memantine on clinical progression in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Clinical Trials as Topic; Cognition; Communication; D | 2012 |
Pharmacological treatment of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; I | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; | 2012 |
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives.
Topics: Alzheimer Disease; Antihypertensive Agents; Aspirin; Cholinesterase Inhibitors; Cognition; Dementia, | 2012 |
Treating the full spectrum of dementia with memantine.
Topics: Aged; Clinical Trials as Topic; Dementia; Disease Progression; Excitatory Amino Acid Antagonists; Hu | 2003 |
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Excitatory Amino Acid | 2004 |
Alzheimer's disease care management plan: maximizing patient care.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Management; Disease Progression; Excitatory Am | 2005 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies.
Topics: Alzheimer Disease; Amyloid; Cholinesterase Inhibitors; Cognition; Combined Modality Therapy; Disease | 2007 |
Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Disability Evaluation; Disea | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indan | 2007 |
History of neuroprotection and rationale as a therapy for glaucoma.
Topics: Disease Progression; Glaucoma; Humans; Memantine; Neurodegenerative Diseases; Neuroprotective Agents | 2008 |
Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dis | 2008 |
14 trials available for memantine and Disease Exacerbation
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind | 2018 |
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Caregivers; Ch | 2014 |
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease.
Topics: Aged; Alleles; Alzheimer Disease; Antipsychotic Agents; Delusions; Disease Progression; Excitatory A | 2014 |
Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Caregivers; Cholinesterase Inhibit | 2015 |
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Biomarkers; Disease Progression; Double-Blind Method; | 2008 |
A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Progression; Excitatory Amino Acid Antag | 2010 |
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication A | 2011 |
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohor | 2012 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
Memantine in moderate-to-severe Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavior; Cognition; Disease Progression; Excit | 2003 |
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.
Topics: Activities of Daily Living; Adolescent; Adult; Disease Progression; Excitatory Amino Acid Antagonist | 2004 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2006 |
Alzheimer's congress. Drug shows promise for advanced disease.
Topics: Alzheimer Disease; Disease Progression; Excitatory Amino Acid Antagonists; Humans; Memantine; Recept | 2000 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
35 other studies available for memantine and Disease Exacerbation
| Article | Year |
|---|---|
Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Humans; Mem | 2022 |
The Differential Diagnosis and Treatment of Mild Cognitive Impairment and Alzheimer Disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Diagnosis, Differential; Diseas | 2022 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progressio | 2020 |
Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Disease Progression; Female; | 2018 |
Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.
Topics: Activities of Daily Living; Amygdala; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Dise | 2018 |
[Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients].
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase | 2013 |
Treatment of the Ppt1(-/-) mouse model of infantile neuronal ceroid lipofuscinosis with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine.
Topics: Animals; Disease Models, Animal; Disease Progression; Excitatory Amino Acid Antagonists; Memantine; | 2013 |
Souvenaid®: a new approach to management of early Alzheimer's disease.
Topics: Alzheimer Disease; Choline; Cholinesterase Inhibitors; Disease Progression; Docosahexaenoic Acids; D | 2014 |
[Vitamin E delays Alzheimer disease progression only slightly].
Topics: Aged; Alzheimer Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Humans | 2014 |
Memantine for treatment of moderate or severe Alzheimer's disease patients in urban China: clinical and economic outcomes from a health economic model.
Topics: Alzheimer Disease; China; Cost Savings; Disease Progression; Excitatory Amino Acid Antagonists; Huma | 2015 |
Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer's Disease over a Three-Year Period: Kuopio ALSOVA Study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Drug Therapy, Co | 2015 |
Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.
Topics: Ammonia; Animals; Brain; Disease Models, Animal; Disease Progression; Dizocilpine Maleate; Excitator | 2008 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Human | 2008 |
New developments in the treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atrophy; Biomarkers; Brain; Choli | 2009 |
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Data Interpretation, Statistical; Di | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; N | 2009 |
CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Disease Progr | 2011 |
Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments.
Topics: Alzheimer Disease; Disease Progression; Excitatory Amino Acid Antagonists; Humans; Memantine; Meta-A | 2011 |
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disord | 2011 |
Huntington's disease: effect of memantine on FDG-PET brain metabolism?
Topics: Adult; Brain; Disease Progression; Excitatory Amino Acid Antagonists; Glucose; Humans; Huntington Di | 2011 |
Drugs: a tangled web of targets.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; An | 2011 |
Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Excitatory A | 2012 |
Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Cholinesterase Inhibitors; Cohort Stu | 2012 |
Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Disease Progression; Double-Blind Method; Excitatory Ami | 2012 |
Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.
Topics: Aging; Animals; Cerebral Cortex; Disease Models, Animal; Disease Progression; Dose-Response Relation | 2012 |
[Prevention of dementias: state of the art].
Topics: Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2003 |
Academic highlights: emerging therapeutic strategies in Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Combined Modality Therapy; Diagnosis, Differential; Disease Progression; D | 2004 |
Memantine and progressive glaucoma.
Topics: Aged; Complementary Therapies; Disease Progression; Excitatory Amino Acid Antagonists; Female; Filte | 2005 |
Alzheimer disease, in living color.
Topics: Alzheimer Disease; Animals; Disease Progression; Humans; Magnetic Resonance Imaging; Memantine; Mice | 2005 |
Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.
Topics: Age of Onset; Aged; Antiparkinson Agents; Brain; Cognition Disorders; Disease Progression; Hallucina | 2005 |
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Cost-Benefit Analysis; Disease Progr | 2005 |
Primary progressive aphasia.
Topics: Aphasia, Primary Progressive; Cholinesterase Inhibitors; Disease Progression; Donepezil; Humans; Ind | 2007 |
Some treatment dilemmas in rapidly developing dementia: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Depression; Diseas | 2008 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantami | 2008 |
Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine.
Topics: Animals; Blood-Brain Barrier; Body Weight; Corticosterone; Disease Progression; Encephalomyelitis, A | 2002 |